Selective TNF-α inhibitor-induced injection site reactions

Bibliography

• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20
   PubMed Web of Science ®Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents–a guide for GPs. Aust Fam Physician 2007;36:1035-8
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Lebwohl MG, Plevy SE, The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Dröll B, Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10
   PubMedGoogle Scholar
• Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008;83:181-94
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52:1481-4
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008;27:541-2
   PubMed Web of Science ®Google Scholar
• Gonnet-Gracia C, Barnetche T, Richez C, Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008;26:401-7
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
   PubMed Web of Science ®Google Scholar
• Berthelot CN, Gorge SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 2005;53(5 Suppl 1):S260-2
   PubMed Web of Science ®Google Scholar
• Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology 2008;4:376-7
   Google Scholar
• Montanè E, Salles M, Barriocanal A, Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007;26:1527-9
   PubMed Web of Science ®Google Scholar
• El-Hag K, Dercken HG, Prenzel R, Hölzle E. [Drug-induced alveolitis associated with infliximab/azathioprine therapy]. Pneumologie 2008;62:204-8
   PubMedGoogle Scholar
• Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68(9):1781-90
   PubMed Web of Science ®Google Scholar
• Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999;83:665-700
   PubMedGoogle Scholar
• deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;278:1895-906
   PubMed Web of Science ®Google Scholar
• Anderson JA, Adkinson NF Jr. Allergic reactions to drugs and biologic agents. JAMA 1987;258:2891-9
   PubMed Web of Science ®Google Scholar
• Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol 2003;24(7):376-9
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Adverse side effects to biological agents. Allergy 2006;61(8):912-20
   PubMed Web of Science ®Google Scholar
• Zeltser R, Valle L, Tanck C, Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein. Arch Dermatol 2001;137(7):893-9
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15(5):280-94
   PubMedGoogle Scholar
• González-López MA, Martínez-Taboada VM, González-Vela MC, Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32(6):672-4
   PubMed Web of Science ®Google Scholar
• Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Inmunol 1999;103:192-9
   PubMed Web of Science ®Google Scholar
• Werth VP, Levinson AI. Etanercept-induced injection site reactions. mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol 2001;137:953-5
   PubMed Web of Science ®Google Scholar
• Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis like reaction to subcutaneous etanercept injection. Arch Dermatol 2006;142(2):218-20
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(2):353-63
   PubMed Web of Science ®Google Scholar
• Dore RK, Mathews S, Schechtman J, The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763-9
   PubMed Web of Science ®Google Scholar
• de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(4):531-5
   PubMed Web of Science ®Google Scholar
• Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J 2009;102(3):304-5
   PubMed Web of Science ®Google Scholar
• Skyttä E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000;18(4):533-4
   PubMed Web of Science ®Google Scholar
• Benucci M, Manfredi M, Demoly P, Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008;63(1):138-9
   PubMed Web of Science ®Google Scholar
• Bavbek S, Aydın O, Ataman S, Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011;66(9):1256-7
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48(1):35-45
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52- week trial. Arthritis Rheum 2004;50(5):1400-11
   PubMed Web of Science ®Google Scholar
• Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7(5):393-403
   PubMed Web of Science ®Google Scholar
• Paltiel M, Gober LM, Deng A, Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 2008;144(9):1190-4
   PubMed Web of Science ®Google Scholar
• Kaneko A, Hirano Y, Fujibayashi T, Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol 2012; In press
   Google Scholar
• Benucci M, Manfredi M, Testi S, Spondyloarthritis presenting with an allergic immediate systemic reaction to adalimumab in a woman: a case report. J Med Case Rep 2011;5:155
   PubMedGoogle Scholar
• Beuthien W, Mellinghoff HU, von Kempis J. Skin Reaction to Adalimumab. Arthritis Rheum 2004;50(5):1690-2
   PubMed Web of Science ®Google Scholar
• Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997;19:127-32
   PubMed Web of Science ®Google Scholar